Literature DB >> 19622537

Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges.

Stephen Crystal1, Mark Olfson, Cecilia Huang, Harold Pincus, Tobias Gerhard.   

Abstract

Atypical antipsychotic medications are increasingly used for a wide range of clinical indications in diverse populations, including privately and publicly insured youth and elderly nursing home residents. These trends heighten policy challenges for payers, patients, and clinicians related to appropriate prescribing and management, patient safety, and clinical effectiveness. For clinicians and patients, balancing risks and benefits is challenging, given the paucity of effective alternative treatments. For health care systems, regulators, and policymakers, challenges include developing the evidence base on comparative risks and benefits; defining measures of treatment quality; and implementing policies that encourage evidence-based practices while avoiding unduly burdensome restrictions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622537      PMCID: PMC2896705          DOI: 10.1377/hlthaff.28.5.w770

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  28 in total

1.  Datapoints: use of multiple psychotropic drugs by Medicaid-insured and privately insured children.

Authors:  Andrés Martin; Tierney Sherwin; Dorothy Stubbe; Thomas Van Hoof; Lawrence Scahill; Douglas Leslie
Journal:  Psychiatr Serv       Date:  2002-12       Impact factor: 3.084

2.  Principles of educational outreach ('academic detailing') to improve clinical decision making.

Authors:  S B Soumerai; J Avorn
Journal:  JAMA       Date:  1990-01-26       Impact factor: 56.272

3.  National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

Authors:  Mark Olfson; Carlos Blanco; Linxu Liu; Carmen Moreno; Gonzalo Laje
Journal:  Arch Gen Psychiatry       Date:  2006-06

4.  Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.

Authors:  Todd P Gilmer; Christian R Dolder; David P Folsom; William Mastin; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2007-07       Impact factor: 3.084

5.  Medicaid's prior authorization program and access to atypical antipsychotic medications.

Authors:  Jennifer M Polinski; Philip S Wang; Michael A Fischer
Journal:  Health Aff (Millwood)       Date:  2007 May-Jun       Impact factor: 6.301

Review 6.  Printed educational materials: effects on professional practice and health care outcomes.

Authors:  Anna P Farmer; France Légaré; Lucile Turcot; Jeremy Grimshaw; Emma Harvey; Jessie L McGowan; Fredric Wolf
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

7.  Issues for DSM-V: adding problem codes to facilitate assessment of quality of care.

Authors:  Michael B First; Harold Alan Pincus; Michael Schoenbaum
Journal:  Am J Psychiatry       Date:  2009-01       Impact factor: 18.112

8.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

9.  Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit.

Authors:  Joyce C West; Joshua E Wilk; Irvin L Muszynski; Donald S Rae; Maritza Rubio-Stipec; Carol L Alter; William E Narrow; Darrel A Regier
Journal:  Am J Psychiatry       Date:  2007-05       Impact factor: 18.112

10.  Medicare Part D prescription drug benefits and administrative burden in the care of dually eligible psychiatric patients.

Authors:  Joshua E Wilk; Joyce C West; Donald S Rae; Maritza Rubio-Stipec; Jennifer J Chen; Darrel A Regier
Journal:  Psychiatr Serv       Date:  2008-01       Impact factor: 3.084

View more
  76 in total

1.  Are commonly used psychoactive medications associated with lower urinary tract symptoms?

Authors:  Susan A Hall; Nancy N Maserejian; Carol L Link; William D Steers; John B McKinlay
Journal:  Eur J Clin Pharmacol       Date:  2011-12-04       Impact factor: 2.953

Review 2.  Challenge of changing nursing home prescribing culture.

Authors:  Jennifer Tjia; Jerry H Gurwitz; Becky A Briesacher
Journal:  Am J Geriatr Pharmacother       Date:  2012-01-20

3.  Off-label use of atypical antipsychotics: cause for concern?

Authors:  Andrew McKean; Erik Monasterio
Journal:  CNS Drugs       Date:  2012-05-01       Impact factor: 5.749

4.  Medication use and spending trends among children with ADHD in Florida's Medicaid program, 1996-2005.

Authors:  Catherine A Fullerton; Arnold M Epstein; Richard G Frank; Sharon-Lise T Normand; Christina X Fu; Thomas G McGuire
Journal:  Psychiatr Serv       Date:  2012-02-01       Impact factor: 3.084

5.  Mortality in children and adolescents prescribed antipsychotic medication: a retrospective cohort study using the UK general practice research database.

Authors:  Fariz A Rani; Patrick Byrne; Noel Cranswick; Macey L Murray; Ian C K Wong
Journal:  Drug Saf       Date:  2011-09-01       Impact factor: 5.606

6.  Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects.

Authors:  Gary Remington; Margaret Hahn
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

7.  Community child psychiatric medication experiences measured by an internet-based, prospective parent survey of retail pharmacy customers.

Authors:  Robert Hilt; Christine Wolf; Kent Koprowicz; Elizabeth Thomas; Mary Chandler; Xiao Lei Hao; Matthew Russell; Tung Le; Lee Hooks; Bryan King
Journal:  Community Ment Health J       Date:  2013-12-10

8.  Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics.

Authors:  Angie Mae Rodday; Susan K Parsons; Catherine Mankiw; Christoph U Correll; Adelaide S Robb; Bonnie T Zima; Tully S Saunders; Laurel K Leslie
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-04-28       Impact factor: 2.576

9.  Psychotropic medication treatment of adolescents: results from the National Comorbidity Survey-Adolescent Supplement.

Authors:  Mark Olfson; Jian-Ping He; Kathleen Ries Merikangas
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-03-07       Impact factor: 8.829

Review 10.  Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.

Authors:  David Linton; Alasdair M Barr; William G Honer; Ric M Procyshyn
Journal:  Curr Psychiatry Rep       Date:  2013-05       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.